The Caire Cash Flow Management Program, which allows providers to purchase a complete oxygen setup for only $54 per month for 36 months with free shipping.
A new paper showed improved pulmonary outcomes with use of the AffloVest in patients with respiratory conditions.
Severe emphysema patients treated with Zephyr Endobronchial Valves (EBV) showed durable improvements in lung function, exercise capacity and quality of life at one year.
ResMed has announced its plans to bring cloud connectivity and AirView, its remote patient monitoring software, to its Astral life support ventilators.
The FDA has issued an advisory against the use of fluoroquinolone antibacterial drugs, such as Cipro or Avelox, for patients with certain respiratory or urinary tract infections.
Daily use of the Aerobika device for three to four weeks produced significant improvements in clinical and patient reported outcomes for COPD.
In a recent study, mortality did not decrease in patients with COPD and cardiovascular disease risk who took fluticasone furoate, vilanterol, or a combination of the two.
Philips’ computed tomography (CT) solutions suite has just been granted 510(k) clearance from the US Food and Drug Administration for low-dose lung cancer screening.
The 5-year deal calls for Masimo to provide the devices to the US Army, Navy, Air Force, Marine Corps and federal civilian agencies.
A Dignity Health study indicates that the use of digital health technology is an effective way to improve asthma control.
PremieBreathe, a portable infant respiratory device, is being developed by students at Yale University to help treat premature infants in the developing world.
The US FDA has approved Bevespi Aerosphere inhalation aerosol indicated for the long-term, maintenance treatment of airflow obstruction in patients with COPD.
3M Drug Delivery Systems has developed the 3M Intelligent Control Inhaler, which is described as an intuitive device designed to deliver accurate doses of medication.
ResApp has raised $9.74 million for its new smartphone-based system designed to diagnose respiratory ailments.
The new website provides greater insight into Nihon Kohden’s products that help professionals across the healthcare system improve the quality of care while controlling costs.
The antimicrobial agent Mul-1867 for the treatment of bacterial lung infections in cystic fibrosis patients has been granted Orphan Drug Designation by the FDA.
The FDA has accepted Genentech’s Biologics License Application and granted Priority Review for the its product atezolizumab for the treatment of non-small cell lung cancer.
Raptor Pharmaceutical Corp has announced its first commercial sale of Quinsair, a levofloxacin inhalation solution for cystic fibrosis treatment, in Germany and Denmark.
RT consulted with some leading device manufacturers about today’s airway clearance products and the industry and technology trends in the next few years.
Several types of aerosol delivery technology exist on the market today, but depending on the specific disease being treated, certain devices may make more sense for patients.